ReviewNature clinical practice. Cardiovascular medicine2009
The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease.
Review in Nature clinical practice. Cardiovascular medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 111 citations in OpenAlex.
- Increased adipose tissue expression of IL-18R and its ligand IL-18 associates with inflammation and insulin resistance in obesity.Immunity, inflammation and disease · 2017Trial
- Trial
- Circulating levels of IL-18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an observational study.Cardiovascular diabetology · 2011Trial
- Interleukin-17, Interleukin-18, T Regulatory Cells, and T-Helper 17 (Th17) Cells Play a Role in Heart Failure: A Systematic Review and Meta-Analysis.Cardiology research and practice · 2026Review
- Comorbidity of hypertension and lung cancer: interplay of genetics and environment.Discover oncology · 2025Review
- Monocyte-to-Neutrophil Ratio as an Immunological Marker of Left Ventricular Hypertrophy in Children with Primary Hypertension.Journal of clinical medicine · 2025Article
- Comprehensive mini-review: therapeutic potential of cannabigerol - focus on the cardiovascular system.Frontiers in pharmacology · 2025Review
- Inflammasomes: novel therapeutic targets for metabolic syndrome?Frontiers in endocrinology · 2025Review
- Early prediction of preeclampsia using the first trimester vaginal microbiome.bioRxiv : the preprint server for biology · 2024Article
- Article
- The Impact of Thyroiditis on the Immune Profile in Young Patients with Uncomplicated Type 1 Diabetes.International journal of molecular sciences · 2024Article
- Immune and inflammatory mechanisms in hypertension.Nature reviews. Cardiology · 2024Review
- The association between the urinary chromium and blood pressure: a population-based study.BMC cardiovascular disorders · 2024Article
- Vascular damage in systemic lupus erythematosus.Nature reviews. Nephrology · 2024Review
- Investigating gut microbiota-blood and urine metabolite correlations in early sepsis-induced acute kidney injury: insights from targeted KEGG analyses.Frontiers in cellular and infection microbiology · 2024Observational
- Inhibition of miR-25 Ameliorates Cardiac Dysfunction and Fibrosis by Restoring Krüppel-like Factor 4 Expression.International journal of molecular sciences · 2023Article
- Systematic characterization of regulatory variants of blood pressure genes.Cell genomics · 2023Article
- Sex Differences in Association Between Gut Microbiome and Essential Hypertension Based on Ambulatory Blood Pressure Monitoring.Hypertension (Dallas, Tex. : 1979) · 2023Article
- Article
- Lumbar spine intervertebral disc desiccation is associated with medical comorbidities linked to systemic inflammation.Archives of orthopaedic and trauma surgery · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding the mechanism by which chronic high blood pressure induces vascular disease is of fundamental importance for prevention of the adverse consequences of hypertension. Clinical and population studies have consistently found increased circulating levels of interleukin 18 (IL-18) in patients with hypertension. Although obesity, and possibly age, is a determinant of plasma IL-18 levels, the relationship of IL-18 to hypertension seems to be independent of these factors. Experimental evidence indicates that the expression of IL-18 and/or its receptor can be induced by catecholamines or angiotensin, two factors that are involved in the pathophysiology of hypertension. Elevated circulating IL-18 levels are associated with vascular changes in the carotid artery, including increased carotid intima-media thickness, which, in turn, is a predictor of cardiovascular events in patients with established coronary disease. IL-18, either directly or through oxidative stress pathways and matrix metalloproteins, can alter endothelial function or induce vascular smooth muscle cell migration and/or proliferation to produce the vascular changes that occur with hypertension. This Review examines the data on IL-18 and hypertensive vascular disease, and explores the potential cellular and molecular mechanisms that might connect hypertension to vascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.